And.

P.W.T l 28 l R3

[And. @andmorenoo]

Nunca quiero olvidar este día, un sueñooooo🧡. #TFTWTOUR #JustinTimberlake

[HONNE @hellohonne]

¡México, te queremos! 🇲🇽 what an incredible start to our 10 year anniversary tour ❤️

[beck @cardgani]

estar en la boda de dua lipa

[PETHEMA @_pethema]

El grupo PETHEMA publica el protocolo “LMA-RR-On” para el manejo de la leucemia mieloblástica aguda en recaída/refractariedad.
Incluye estratificación fit/unfit, uso de FLAG-IDA, gilteritinib en FLT3+ y diagnóstico molecular centralizado vía PLATAFO-LMA. #LMA #AML #Hematología

[HONNE @hellohonne]

i
still
think
of
you
a
hundred
times
a
day
♡

[HONNE @hellohonne]

Warm on a Cold Night (feat. Wind, Man and Cute Dog)

[Grey's Anatomy @Greysloanok]

McSteamy 🕊️

[And. @andmorenoo]

Gracias a las MGUS que me hicieron encontrar un camino más bonito para mí, neta can’t wait 🥹

[And. @andmorenoo]

I love Dr Tripp. Una playera que diga 💘

[And. @andmorenoo]

@belderrainmn No te vayas chavo :(

[Journal of Brown Hospital Medicine @BrownJHM]

Tumor lysis syndrome @PedsCases #medEd

[And. @andmorenoo]

Wey cada quien en su rotación ptm 🫩🫩

[Florencia María @flortundis]

Último día del 2025

[And. @andmorenoo]

Mi primer colapso mamón del R2 🫩

[And. @andmorenoo]

Regálame un kindle y te digo que pienso de ti.

[And. @andmorenoo]

NOSTOY ME FUI A VER A DUA LIPA 🙂‍↕️

[AmericanJournalofHematology @AjHematology]

New real-world data on #Gilteritinib in relapsed/refractory #FLT3-mutated #AML: treatment beyond 2nd line remains effective and enables transplant in selected patients. Study of 171 cases across 4 countries. #Leukemia #Hematology
https://t.co/PwhP16bklB @jadothm

[A @andres_pinot]

SI SE PUDOOO LLEGAMOS AL VIERNES

[And. @andmorenoo]

Que amanezca con dolor de cabeza significa que mi día laboral estará dlv. Y sí en efecto.

[Dr. Chokri Ben Lamine @abouabdrahman0]

🧬🔥 AZA-VEN in AML — “How I Treat” (Wei, Lee, Daver et al.)
— Hema Consultant Level

📌 General Principles
• 🧓 For unfit patients → AZA-VEN per ELN 2024.
• 🏥 Consider inpatient start if prolonged neutropenia expected.
• ⚠️ Minimize TLS risk:
 — 🔬 High-risk features: IDH2 mutation, very high WBC, ↑LDH, ↑uric acid, renal impairment
 — 📉 Reduce WBC to <15 ×10⁹/L (or ideally <10 ×10⁹/L).
 — 💧 Aggressive hydration + TLS prophylaxis.
 — 🏥 Inpatient monitoring during cycle 1 for high-risk pts.
 — 🔄 If on CYP3A4 inhibitor → reduce VEN dose and plateau sooner.

🧱 Venetoclax + Azacitidine Backbone
• VEN: standard ramp-up unless TLS risk → flatten ramp.
• AZA: per usual schedule (75 mg/m² × 7 days).

🩸 Neutropenic Phase (Cycle 1)
• 🏥 If inpatient → follow intensive-chemo level antimicrobial strategy.
• 🛡️ Broad antimicrobial prophylaxis (antibacterial, antifungal, antiviral).
• 🔎 Intensify monitoring → early detection of infections.

🧪 Response Assessment (C1 Days 21–28)
• 🔬 If blast clearance → interrupt VEN to allow count recovery.
• 📉 If ANC <0.5 ×10⁹/L → consider G-CSF.
• 🔁 Resume therapy once counts recover before starting Cycle 2.

🔄 Subsequent Cycles
• 🩸 Allow full recovery:
 — ANC ≥1.0 ×10⁹/L
 — Platelets ≥100 ×10⁹/L
• If delayed recovery (common 5–42 days):
 — ✂️ Shorten VEN duration
 — ⏳ Increase interval between cycles
 — 📉 Reduce AZA dose

🟥 Critical Consultant Pearl
📣 “More venetoclax” ≠ “better venetoclax.”
Prolonged or excessive VEN → damages normal stem cells.
🎯 Goal = optimal VEN exposure (not maximal).
Ref: Wei et al., Blood 2024; DOI: 10.1182/blood.2024024009

#AML #Venetoclax #Azacitidine #ELN2024 #Hematology #SOHO #ASH #ESHEmiratesHematologySociety